. . . "Vnit\u0159n\u00ED l\u00E9ka\u0159stv\u00ED" . . "4"^^ . "59" . "Primary hyperaldosteronism: common cause of secondary hypertension with higher cardiovascular risk"@en . "1"^^ . "I" . . . "1"^^ . . "Prim\u00E1rn\u00ED hyperaldosteronizmus (PH) je nej\u010Dast\u011Bj\u0161\u00ED p\u0159\u00ED\u010Dina nejen endokrinn\u00ED, ale i sekund\u00E1rn\u00ED hypertenze vyvolan\u00E1 autonomn\u00ED nadprodukc\u00ED mineralokortikoid\u016F (aldosteronu) k\u016Frou nadledvin s vysok\u00FDmi hladinami aldosteronu, potla\u010Den\u00FDm reninem a arteri\u00E1ln\u00ED hypertenz\u00ED. Nemocn\u00ED s PH maj\u00ED ve srovn\u00E1n\u00ED s esenci\u00E1ln\u00ED hypertenz\u00ED vy\u0161\u0161\u00ED riziko subklinick\u00E9ho org\u00E1nov\u00E9ho po\u0161kozen\u00ED (nap\u0159. zv\u00FD\u0161en\u00ED IMT karotid, zv\u00FD\u0161en\u00ED tuhosti velk\u00FDch tepen, zv\u00FD\u0161en\u00FD v\u00FDskyt mikroalbuminurie) a zv\u00FD\u0161en\u00E9 riziko kardiovaskul\u00E1rn\u00EDch komplikac\u00ED, co\u017E m\u016F\u017Ee b\u00FDt zp\u016Fsobeno t\u011B\u017Ekou hypertenz\u00ED, mnohdy rezistentn\u00ED na l\u00E9\u010Dbu. Krom\u011B vysok\u00E9ho tlaku se zde m\u016F\u017Ee negativn\u011B uplat\u0148ovat komplexn\u00ED negativn\u00ED p\u016Fsoben\u00ED nadbytku aldosteronu/aktivace mineralokortikoidn\u00EDch receptor\u016F v nejr\u016Fzn\u011Bj\u0161\u00EDch tk\u00E1n\u00EDch. \u010Casn\u00E1 specifick\u00E1 terapie PH m\u016F\u017Ee v\u00E9st k \u010D\u00E1ste\u010Dn\u011B regresi zn\u00E1mek subklinick\u00E9ho org\u00E1nov\u00E9ho po\u0161kozen\u00ED a ke sn\u00ED\u017Een\u00ED KV rizika. D\u00EDky vysok\u00E9 prevalenci PH v populaci hypertonik\u016F je tak nezbytn\u00E1 \u010Dasn\u00E1 diagnostika tohoto onemocn\u011Bn\u00ED s p\u0159esn\u00FDm odli\u0161en\u00EDm jednotliv\u00FDch forem a brzk\u00FDm zah\u00E1jen\u00EDm specifick\u00E9 terapie (konzervativn\u00ED vs chirurgick\u00E1)." . "Widimsk\u00FD, Ji\u0159\u00ED" . . "Primary hyperaldosteronism: common cause of secondary hypertension with higher cardiovascular risk"@en . "[A27FEA5B7EAD]" . . "99276" . "Prim\u00E1rn\u00ED hyperaldosteronizmus (PH) je nej\u010Dast\u011Bj\u0161\u00ED p\u0159\u00ED\u010Dina nejen endokrinn\u00ED, ale i sekund\u00E1rn\u00ED hypertenze vyvolan\u00E1 autonomn\u00ED nadprodukc\u00ED mineralokortikoid\u016F (aldosteronu) k\u016Frou nadledvin s vysok\u00FDmi hladinami aldosteronu, potla\u010Den\u00FDm reninem a arteri\u00E1ln\u00ED hypertenz\u00ED. Nemocn\u00ED s PH maj\u00ED ve srovn\u00E1n\u00ED s esenci\u00E1ln\u00ED hypertenz\u00ED vy\u0161\u0161\u00ED riziko subklinick\u00E9ho org\u00E1nov\u00E9ho po\u0161kozen\u00ED (nap\u0159. zv\u00FD\u0161en\u00ED IMT karotid, zv\u00FD\u0161en\u00ED tuhosti velk\u00FDch tepen, zv\u00FD\u0161en\u00FD v\u00FDskyt mikroalbuminurie) a zv\u00FD\u0161en\u00E9 riziko kardiovaskul\u00E1rn\u00EDch komplikac\u00ED, co\u017E m\u016F\u017Ee b\u00FDt zp\u016Fsobeno t\u011B\u017Ekou hypertenz\u00ED, mnohdy rezistentn\u00ED na l\u00E9\u010Dbu. Krom\u011B vysok\u00E9ho tlaku se zde m\u016F\u017Ee negativn\u011B uplat\u0148ovat komplexn\u00ED negativn\u00ED p\u016Fsoben\u00ED nadbytku aldosteronu/aktivace mineralokortikoidn\u00EDch receptor\u016F v nejr\u016Fzn\u011Bj\u0161\u00EDch tk\u00E1n\u00EDch. \u010Casn\u00E1 specifick\u00E1 terapie PH m\u016F\u017Ee v\u00E9st k \u010D\u00E1ste\u010Dn\u011B regresi zn\u00E1mek subklinick\u00E9ho org\u00E1nov\u00E9ho po\u0161kozen\u00ED a ke sn\u00ED\u017Een\u00ED KV rizika. D\u00EDky vysok\u00E9 prevalenci PH v populaci hypertonik\u016F je tak nezbytn\u00E1 \u010Dasn\u00E1 diagnostika tohoto onemocn\u011Bn\u00ED s p\u0159esn\u00FDm odli\u0161en\u00EDm jednotliv\u00FDch forem a brzk\u00FDm zah\u00E1jen\u00EDm specifick\u00E9 terapie (konzervativn\u00ED vs chirurgick\u00E1)."@cs . . . "Prim\u00E1rn\u00ED hyperaldosteronizmus: \u010Dast\u00E1 forma sekund\u00E1rn\u00ED hypertenze s vy\u0161\u0161\u00EDm kardiovaskul\u00E1rn\u00EDm rizikem" . "6" . "CZ - \u010Cesk\u00E1 republika" . "Prim\u00E1rn\u00ED hyperaldosteronizmus: \u010Dast\u00E1 forma sekund\u00E1rn\u00ED hypertenze s vy\u0161\u0161\u00EDm kardiovaskul\u00E1rn\u00EDm rizikem" . . . "RIV/00064165:_____/13:10193865" . "http://www.prolekare.cz/linkout/40884" . "cardiovascular risk; hypertension; Primary aldosteronism"@en . . "Prim\u00E1rn\u00ED hyperaldosteronizmus: \u010Dast\u00E1 forma sekund\u00E1rn\u00ED hypertenze s vy\u0161\u0161\u00EDm kardiovaskul\u00E1rn\u00EDm rizikem"@cs . "0042-773X" . "Prim\u00E1rn\u00ED hyperaldosteronizmus: \u010Dast\u00E1 forma sekund\u00E1rn\u00ED hypertenze s vy\u0161\u0161\u00EDm kardiovaskul\u00E1rn\u00EDm rizikem"@cs . "Primary hyperaldosteronism (PH) is common cause of secondary hypertension with autonomous aldosterone overproduction by adrenal cortex with high plasma aldosterone, suppressed renin and high blood pressure. Patients with PH have compared to essential hypertension (EH) more frequent sublinical organ damage and higher cardiovascular risk (CV). Higher carotid IMT, arterial stiffness and microalbuminuria was found in PH. Early specific therapy of PH may lead to the regression of target organ damage and decrease of CV risk. Early diagnostic and therapeutic measures are very important due to high prevalence of PH."@en . "RIV/00064165:_____/13:10193865!RIV14-MZ0-00064165" . .